Reducing the risk of recurrent stroke in patients with AF

The Lancet Neurology

Volumn 11, Issue 6, 2012, Pages 479-481

  Hart, Robert G ^a   Eikelboom, John W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; HEPARIN; WARFARIN; DABIGATRAN; RIVAROXABAN;

BRAIN HEMORRHAGE; DRUG EFFICACY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; ANTICOAGULATION; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HEART ATRIUM APPENDAGE; INTERVENTION STUDY; NOTE; PERSONAL EXPERIENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; PYRAZOLES; PYRIDONES; STROKE; WARFARIN;

EID: 84861186489     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70096-0     Document Type: Letter

References (12)

1. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69:546-554. Stroke Risk in Atrial Fibrillation Working Group.
2. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
3. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
4. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW Factors associated with stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III trials. Stroke 1999, 30:1223-1229.
5. Hart RG, Pearce LA, Koudstaal PJ Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention. Stroke 2004, 35:948-951.
6. Hart RG, Pearce LA, Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
7. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1998, 31:622-626.
8. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012, for the ARISTOTLE Committees and Investigators, published online May 8. 10.1016/S1474-4422(12)70092-3.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
11. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120:700-705.
12. Hart RG, Palacio S, Pearce LA Atrial fibrillation, stroke and acute antithrombotic therapy. Analysis of randomized clinical trials. Stroke 2002, 33:2722-2727.